A phase Ib study of everolimus combined with metformin for patients with advanced cancer

Background The efficacy to monotherapy with the mTOR inhibitor everolimus in advanced cancer is often limited due to therapy resistance. Combining everolimus with metformin may decrease the chance of therapy resistance. Methods Patients received everolimus and metformin in a 3 + 3 dose-escalation sc...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Invest New Drugs
मुख्य लेखकों: Molenaar, Remco J., van de Venne, Tim, Weterman, Mariëtte J., Mathot, Ron A., Klümpen, Heinz-Josef, Richel, Dick J., Wilmink, Johanna W.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Springer US 2017
विषय:
Phase I Studies
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5805805/
https://ncbi.nlm.nih.gov/pubmed/28616837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-017-0478-4
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन